These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9481469)

  • 21. Respiratory syncytial virus and innate immunity: a complex interplay of exploitation and subversion.
    Johnson TR
    Expert Rev Vaccines; 2006 Jun; 5(3):371-80. PubMed ID: 16827621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Respiratory syncytial virus: reverse genetics and vaccine strategies.
    Collins PL; Murphy BR
    Virology; 2002 May; 296(2):204-11. PubMed ID: 12069519
    [No Abstract]   [Full Text] [Related]  

  • 23. [Illnesses by the human respiratory syncytial virus].
    Stock I
    Med Monatsschr Pharm; 2006 Sep; 29(9):329-34, 335-6. PubMed ID: 16984081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab).
    National Advisory Committee on Immunization
    Can Commun Dis Rep; 2003 Sep; 29():1-15. PubMed ID: 14524195
    [No Abstract]   [Full Text] [Related]  

  • 25. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines.
    Durbin AP; Karron RA
    Clin Infect Dis; 2003 Dec; 37(12):1668-77. PubMed ID: 14689350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of the rapid antigenic test to determine the duration of isolation in infants hospitalized for respiratory syncytial virus infections.
    Myers C; Wagner N; Kaiser L; Posfay-Barbe K; Gervaix A
    Clin Pediatr (Phila); 2008 Jun; 47(5):493-5. PubMed ID: 18509148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the seroprevalence of human metapneumovirus and human respiratory syncytial virus.
    Ebihara T; Endo R; Kikuta H; Ishiguro N; Ishiko H; Kobayashi K
    J Med Virol; 2004 Feb; 72(2):304-6. PubMed ID: 14695674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Involvement of antibody, complement and cellular immunity in the pathogenesis of enhanced respiratory syncytial virus disease.
    Delgado MF; Polack FP
    Expert Rev Vaccines; 2004 Dec; 3(6):693-700. PubMed ID: 15606354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The other effect of intravenously administered respiratory syncytial virus-enriched immune globulin for prophylaxis: less acute otitis media.
    Harrison CJ
    J Pediatr; 1996 Aug; 129(2):193-6. PubMed ID: 8765615
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical pictures of children with human metapneumovirus infection: comparison with respiratory syncytial virus infection.
    Kashiwa H; Shimozono H; Takao S
    Jpn J Infect Dis; 2004 Apr; 57(2):80-2. PubMed ID: 15118218
    [No Abstract]   [Full Text] [Related]  

  • 31. [Respiratory syncytial virus infection in childhood].
    Hammer J
    Schweiz Med Wochenschr; 1998 Sep; 128(37):1366-74. PubMed ID: 9783360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B; Steele S; Janes M; Pinelli J
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Is it smart to give immunoglobulin prophylaxis against respiratory syncytial virus infection?].
    Greisen G
    Ugeskr Laeger; 2001 Nov; 163(47):6607. PubMed ID: 11760548
    [No Abstract]   [Full Text] [Related]  

  • 35. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients.
    Collarini EJ; Lee FE; Foord O; Park M; Sperinde G; Wu H; Harriman WD; Carroll SF; Ellsworth SL; Anderson LJ; Tripp RA; Walsh EE; Keyt BA; Kauvar LM
    J Immunol; 2009 Nov; 183(10):6338-45. PubMed ID: 19841167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin.
    Ghosh S; Champlin RE; Englund J; Giralt SA; Rolston K; Raad I; Jacobson K; Neumann J; Ippoliti C; Mallik S; Whimbey E
    Bone Marrow Transplant; 2000 Apr; 25(7):751-5. PubMed ID: 10745261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Respiratory syncytial virus: an important cause of influenza-like disese in the elderly].
    Kolmos HJ
    Ugeskr Laeger; 1996 Dec; 159(1):59-60. PubMed ID: 9012077
    [No Abstract]   [Full Text] [Related]  

  • 38. Reducing the morbidity of lower respiratory tract infections caused by respiratory syncytial virus: still no answer.
    Prober CG; Wang EE
    Pediatrics; 1997 Mar; 99(3):472-5. PubMed ID: 9041306
    [No Abstract]   [Full Text] [Related]  

  • 39. Prevention of respiratory syncytial virus infection in high risk infants.
    Prince AM; Jacobs RF
    J Ark Med Soc; 2001 Oct; 98(4):115-8. PubMed ID: 11594047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human and bovine respiratory syncytial virus vaccine research and development.
    Meyer G; Deplanche M; Schelcher F
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):191-225. PubMed ID: 17720245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.